We investigated the mechanism by which antihuman CD3 monoclonal antibodies of the isotypes lgG2a (eg, OKT3) and IgA (eg, 1XA) can induce the rapid disappearance of virtually all circulating T lymphocytes. We hypothesize that upregulation of adhesion molecules on the lymphocyte membrane contributes to this effect. However, this hypothesis is diffi cult to test, because of the inherent lymphocytopenia and/ or shifts in lymphocyte populations between intra and extravascular compartments. Therefore, studies in vitro were per formed, as well. Analysis of peripheral blood lymphocytes isolated at several times after addition of OKT3 or IXA to whole blood of healthy individuals showed an immediate increase in the proportion of T cells expressing NKI-L16, an activation epitope on CD11a/CD18. Likewise, an increase in I T IS well-established that OKT3, a murine IgG2a mono clonal antibody directed against the CD3 molecule on human T lymphocytes, is a potent immunosuppressive agent in prophylaxis and treatment of acute allograft rejection.1"3 It is generally assumed that the concomitant immediate and profound peripheral blood lymphocytopenia4 is caused by sequestration of OKT3-sensitized T lymphocytes, following binding to Fc-and complement receptors.5'7 However, this cannot be the sole explanation, in particular for the initial phase of T lymphocytopenia. Indeed, previous studies with murine isotype switch variant CD3 monoclonal antibodies in chimpanzees, as well as humans, have shown that the IgG2a, as well as IgA isotypes, can induce an immediate, although transient, lymphocytopenia.8,9 Because neither chimpanzees nor humans express Fc receptors for murine IgA and monomeric IgA is generally assumed to have poor complement-activating capacity,9 the rapidly occurring lymphocytopenia induced by the anti-CD3 monoclonal anti bodies must have other causes. We hypothesize that binding to vascular endothelium via adhesion molecules is instru mental in the rapidly occurring peripheral lymphocytopenia.
T-CELL ADHESION MOLECULES AFTER CD3 MoAb 405 MATERIALS AND METHODS
Methods
The study was approved by the institutional research and ethical committees of the Academic Medical Center of the University of Amsterdam. Written informed consent was obtained from all pa tients.
In Vivo Studies
Patients. Ten renal transplant recipients (three men, seven women, median age 31 years, range, 20 to 61 years) were studied. These patients were treated for 10 consecutive days with 5 mg/day OKT3 (Ortho Diagnostic Systems, Raritan, NJ) because of acute kidney allograft rejection, diagnosed on the basis of clinical manifes tations and confirmed by core biopsy. As recommended by the manu facturer, before OKT3 administration on day 1, a single dose of 500 mg methylprednisolone was given. The control group consisted of 10 renal transplant recipients (four men, six women, median age 31 years, range, 21 to 54 years) who were treated for acute rejection with methylprednisolone 500 mg/day for 6 consecutive days. Basic immunosuppressive therapy in both groups consisted of prednisolone (10 mg/day) and cyclosporin (dosage adjusted so as to result in whole-blood trough levels of 150 to 200 /ig/L).
Materials and methods. Peripheral blood was collected before the administration of 500 mg methylprednisolone and at 3, 10, 15, 30, 60, 120 minutes, 4.5, and 24 hours after administration of either 5 mL (ie, 5 mg) OKT3 or 5 mL 0.9% saline (control group). At each time point, total leukocyte and differential counts were deter mined by flow cytometry (Technicon HI System; Bayer/Technicon, Tarrytown, NY) on blood anticoagulated with 0.38 mmol/L EDTA, Peripheral blood mononuclear cells were isolated by centrifugation of heparinized blood on Ficoll-Paque (density 1.076; Pharmacia, Uppsala, Sweden). Contaminating erythrocytes were Jysed by incu bation with ammoniumchloride (155 mmol/L NH4C1, 10 mmol/L KHCO3, 0.1 mmol/L EDTA, pH 7.4) for 10 minutes on ice, followed by two washings of the mononuclear cells in PBS-A (ie phosphate buffered saline (PBS) containing 0.5% wt/vol bovine serum albumin (Boseral DEM, Organon Teknika B.V., Boxtel, Holland) and 0,01% wt/vol sodium azide).
Immunofluorescence. Peripheral blood mononuclear cells were incubated for 30 minutes at 0°C in PBS-A with appropriate dilutions of the fluorescein isothiocyanate (FITC)-labeled monoclonal anti bodies CD 11a (Dako, Glostrup, Denmark, clone MHM24, IgGlk), NKI-L16'2,13 and CD 16 (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), Amsterdam, The Nether lands; clone CLB-149, IgG2a), and with the phycoerythrin-labeled monoclonal antibody CD! lb (Dako; clone 2LPM19c, IgGlk). For determination of CD62L and CD49d/CD29 expression, an indirect staining procedure was used consisting of primary incubation of the mononuclear cells with appropriate dilutions of the monoclonal antibodies LECAM-1 (directed against CD62L, Becton Dickinson, San Jose, CA; clone SK li, IgG2a, biotinylated) or CD49d (directed against VLA-o;4 chain, Immunotech, Marseille, France; clone HP2.1, IgGl), followed by incubation with phycoerythrin-labeled streptavidin (Becton Dickinson) or FITC-labeled goat antimouse IgGl (Southern Biotechnology, Birmingham, AL), respectively. All sam ples were two-color stained with a phycoerythrin-or FITC-labeled anti-CD2 monoclonal antibody (Dako; clone MT910, IgGlk or Bec ton Dickinson, Leu-5b; clone S5.2, IgG2a, respectively) and with a phycoerythrin-or FITC-labeled anti-CD3 monoclonal antibody (both from Becton Dickinson, Leu-4; clone SK7, IgGl). Determination of the absolute number of CD3 positive cells was performed in two ways: (1) direct labeling with a phycoerythrin-or FITC-labeled anti-CD3 monoclonal antibody (Becton Dickinson, Leu-4; clone SK7, IgGl) and (2) with FITC labeled F(ab')2 fragments of goat antimouse Ig (GAM F(ab')2, obtained from the CLB. Analysis of cell suspen sions was performed on a FACS can (Becton Dickinson). Lympho cytes in the mononuclear cell population were gated on forward and side scatter.
In Vitro Studies
Immunofluorescence. A total of 55 mL heparinized peripheral blood was taken from five healthy individuals and kept in a 37°C waterbath. A 5-mL sample was set apart and the remaining 50 mL blood was divided into four separate portions, to which OKT3, IXA, an irrelevant murine monoclonal antibody of the IgG2a isotype (F23-49, directed against Mycobacterium tuberculosis14) or an irrelevant murine monoclonal antibody of the IgA isotype (clone TEPC15, mouse IgA/c myeloma protein; Sigma, St Louis, MO) was added, each at a final concentration of 1 /¿g/mL, which is comparable to serum levels after administration of 5 mg OKT3 in vivo.15 At 3, 30, and 60 minutes after addition of the monoclonal antibody, 3 mL samples were taken. Peripheral blood mononuclear cells were sepa rated by Ficoll-Paque density gradient centrifugation and expression of the same adhesion molecules as analyzed in the in vivo studies was measured on a FACScan as described above. At each time point, total leukocyte and differential counts were determined by flow cy tometry (Technicon HI System).
Functional Adhesion Studies
From eight healthy individuals, 40 mL heparinized peripheral blood was taken. Mononuclear cells were isolated by cenLrifugation on Ficoll-Paque, followed by three washings in Tris-buffered Earle's Balanced Salt Solution containing 5% fetal calf serum. Next, CD3+ T cells were obtained by a negative selection procedure: removal of B lymphocytes, monocytes, and natural killer cells by incubation with murine monoclonal antibodies anti-CD19 (CLB, clone 11G1), anti-CD 14 (CLB, clone 8G3), and anti-CD16 (CLB, gran-1) fol lowed by incubation with sheep antimouse IgG coated Dynabeads (Dynal A.S, N-0212, Oslo, Norway). This procedure resulted in >95% pure T-cell suspensions as confirmed by fluorescence-activated cell sorter (FACS) analysis after staining the cells with a mixture of FITC-labeled CD3-and phycoerythrin-labeled CD 16 and CD56 monoclonal antibodies (NK-Simulset, Becton Dickinson). The CD3-positive cells (2 X 106 cells/mL) were incubated on ice for 30 minutes with OKT3, IXA, the irrelevant IgG2a monoclonal antibody F23-49, or the irrelevant IgA monoclonal autibody TEPC15, each at a final concentration of 1 /¿g/mL, followed by two washings at 4°C with Iscove's modified Dulbecco's medium containing 5% fetal calf serum. Next, 2 ¿¿g/mL goat antimouse Ig (GM17D, CLB) was added to cross-link the T-cell receptor/CD3 complexes, immediately followed by 3 minutes 10# centrifugation at 37°C.11 Part of the cell suspension was then added to a cell monolayer consisting of an immortalized endothelial cell line derived from human umbilical vein endothelial cells,16 cultured in 96-well plates (Nunclon Micro Well F96, Nunc A.S, Roskilde, Denmark) on \% gelatin (Sigma, G1S90) in PBS. The remaining cell suspension was placed in a shaking waterbath at 37°C and after 30 and 60 minutes of incubation, samples were added to the endothelial cell monolayers. The 96-well plates were incubated for 15 minutes at 37°C in 5% C 0 2, followed by removal of the nonadherent fraction by washing three times with 200 f£L 37°C Earle's Balanced Salt Solution containing 5% fetal calf serum. The adherent fraction was stained with Diff Quick (a 3step staining procedure comprising: (1) fixation in methanol with fast green 0.002 g/L, (2) eosin G in phosphate buffer pH 6,6, and (3) thiazine dye in phosphate buffer pH 6.6 (Baxter Dade A.G, Diidingen, Switzerland). All experiments were performed in tripli cate. As a positive control, the cells were preincubated with phorbol myristate acetate (50 ng/mL, Sigma) instead of a CD3 monoclonal antibody. Blocking studies were performed with monoclonal anti bodies directed against the common /?2 integrin chain (CD 18): TS 1/18,17 against C D lla (NKI-L7),18 and against C D llb (Bear-1 19), added to the endothelial cell monolayer together with the T cells. The final antibody concentration was 10 /xg/mL, which in previous studies was shown to result in a maximal inhibition of adhesion. The adhesion was scored blindly at 200 X magnification by three investigators independently, in a semiquantitative way: 0 -no T cells, 1 * <50 T cells/field, 2 * 50 to 100 T cells/field, 3 = 100 to 250 T cells/field, 4 = 250 to 350 T cells/field, 5 = >350 T cells/ field.
Because it is difficult to estimate the extent to which cross-linking occurs in vivo, since we do not know which part of the administered amount of CD3 monoclonal antibody actually binds to the T cells and which part remains unbound, both the whole blood incubation and adhesion studies were performed with concentrations of OKT3 or IXA ranging from 0.01 to 10 jxgJmL, To exclude the possibility that the expression and functional activity of adhesion molecules was influenced by any antibody not directed to the CD3/T~cell receptor complex, whole blood incubations and adhesion studies were also performed with murine IgG2a monoclonal antibodies directed against either the CD4 molecule (ie> CLB-T4), or a major histocom patibility complex (MHC) class-I antigen (W6/32), instead of the CD3 monoclonal antibody. Both the CD4 and the MHC class-I monoclonal antibody were tested at concentrations of 0.1 , 1, and 10 (iglm h.
Calculations and Statistics
Absolute number o f double-positive cells. This was determined by the percentage of double-positive cells (calculated by means of PCLYSYS software from Bee ton Dickinson) multiplied by the abso lute number of lymphocytes at the same time point. All values are expressed as mean ± standard error of mean (SEM).
Mean fluorescence intensity (MFI). At all time points the MFI was calculated by means of PCLYSYS software. A total of 100% represents the MFI values obtained from the blood samples before the start of treatment. The values obtained several times after admin istration of OKT3 are represented as a percentage of the pretreatment value. All values are expressed as mean ± SEM.
Statistical analysis, Differences within groups were tested by Wilcoxon Test for Matched pairs. A probability (P) value < .05 was considered to indicate a significant difference. Fig 1, treatment with 5 mg OKT3 caused within 3 minutes in all of the 10 patients studied a sharp decline in the number of CD3* peripheral blood lymphocytes (from 1.24 ± 0.15 X 107L to 0.07 ± 0.01 X 107L, P < .05). From 3 minutes on, the number of goat antimouse F(ab')2 positive cells decreased in parallel, while the number of CD3+ cells remained very low during the whole study period. Likewise, the absolute number of CD2'f' peripheral blood lymphocytes showed within 3 minutes a rapid decrease from 1.40 ± 0.16 X 109/L to 0.54 ± 0.06 X 109/L (P < .05). Afterwards, the decrease in CD2 + lymphocytes was more gradual, until a lowest value of 0.08 ± 0.01 X 109/L was reached, persisting for at least 4.5 hours. Only a partial recovery to 0.29 ± 0.11 X 109/L was observed after 24 hours (ie, immediately before administration of the second OKT3 dose). 
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tained before and at 3, 10, 60, 120 minutes, and 24 hours after administration of the first dose of OKT3 are summa rized in Table 1 . The MFI of CD62L on the remaining CD3 positive cells decreased within 120 minutes to 52.41 ± 12.86% of pretreatment value (P < .05). The MFI of CD1 la on the remaining CD2 positive cells showed a 2.5~fold in crease after 3 minutes and remained high for the whole study period, while the MFI of C D lla on the remaining CD3 positive cells increased much less. The MFI of NKI-L16 on the remaining CD3 positive cells showed hardly any change (Table 1) . Before OKT3 administration, 22.86 ± 4.39% of the CD2 positive and 18.55 ± 3.71% of the CD3 positive lymphocytes were C D llb positive. However, from 10 minutes after OKT3 administration, almost all the remain ing CD2+CD3" cells were C D llb positive, and these CDi lb+CD2H ' cells followed the total number of CD2 posi tive lymphocytes. These remaining C D llb +CD2+CD3~ ap peared to be also CD 16 positive (data not shown), a pheno type characteristic for natural killer cells. The MFI of CD 1 lb on the remaining CD2 positive cells showed a 1.8 -fold in crease within 3 minutes following administration of OKT3 and remained high for the whole study period. The MFI of C D llb on the remaining CD3 positive cells also showed a 1.9-fold increase within 10 minutes and remained elevated for at least 4.5 hours. No changes were observed in the percentage of CD49d positive cells or in the MFI of CD49d on the remaining CD2 positive and CD3 positive population after administration of OKT3 (data not shown).
In the 10 patients from the control group (treated with 500 mg methylprednisolone only), the absolute numbers of CD2+ peripheral blood lymphocytes initially increased from 1.53 ± 0.23 X 109/L before drug administration to 1.85 ± 0.20 X 109/L at 10 minutes thereafter. From 15 minutes onwards, the CD2+ cell counts showed a gradual decrease to 0.45 ± 0.02 X 109/L after 4.5 hours. After 24 hours, they had almost completely recovered to 1.35 ± 0.17 X 109/L (Fig 1) . The absolute number of CD3 positive cells remained constant during the first 15 minutes and then decreased and recovered parallel with the CD2 positive cells (Fig 1) . No changes in the expression of the adhesion molecules CD62L, CDlla/CD18, NKI-L16, and CD49d/CD29 were observed from 15 minutes onwards, neither on CD2 positive nor on CD3 positive cells (data not shown). However the absolute number of CDl'lb+CD2+ cells increased, from 0.51 ± 0.06 X 109/L before drug administration to 1.02 ± 0.09 X 109/L at 10 minutes after saline administration, while the absolute number of CD1 lb +CD3+ cells remained constant during this time interval. The MF1 of C D !lb on the remaining CD2 positive and CD3 positive cells showed hardly any change (data not shown). of 1 fig/mL OKT3 or IXA to heparinized blood from five healthy volunteers did not induce any change in the absolute numbers of CD2+ cells, CD3+ cells, and CD16+CD56+CD3" (natural killer) cells and neither did the expression of the adhesion mole cules CD62L, CD1 la/CD18, and CD49d/CD29 on CD2 pos itive and CD3 positive lymphocytes change (data not shown). In contrast, the number of CD3 positive lympho cytes expressing the activation epitope NKI-L16 on the CDlla7CD18 complex, showed a twofold increase within 3 minutes after addition of 1 pg/mL OKT3 (Fig 2A) , followed by a gradual decrease. Addition of 1 /ig/mL IXA also in duced a twofold increase in the number of CD3 positive lymphocytes expressing the NKI-L16 epitope on the CD1 la/ CD 18 complex, although more slowly as compared with OKT3 (Fig 2 B) . No changes were detected in the absolute numbers of C D lIa +CD3~'' cells ( Fig 2 A and B 3A and B) . Both the increase in NKI-L16 and CD1 lb expres sion were dose dependent, reaching a maximal effect with 10 (jig/mL for OKT3 and with 1 /zg/mL for IXA. A total of 0,1 /jg/mL OKT3 or IXA still induced an increased expres sion of both adhesion molecules, but less than that observed with 1 /ig/mL o f each monoclonal antibody, and with 0.01 (iglmL OKT3 or IXA, no changes in adhesion molecule expression were detectable (data not shown). No changes 
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), nor in MFI of NKI-L16 and CD1 la, either after OKT3 or IXA (data not shown). In addition, an immediate increase in MFI of CD1 lb on CD3 positive lymphocytes was observed on incubation with either OKT3 or IXA, reaching a maximum at three times the preaddition value after 60 minutes incubation (Fig
Results are given as mean ± SEM. Open bars, numbers of [NKI-L16]+CD3+ cells after irrelevant isotype control antibodies; solid bars, number of [NKI-Ll6]+CD3+ cells after OKT3 (A) or IXA (B); crosshatched bars, number of C D 1la+CD3* cells after OKT3 (A) or IXA (B).
occurred in the expression of NKI-L16 or C D llb on CD3 positive cells in control samples incubated with murine IgG2a monoclonal antibodies directed against either the CD4 molecule or against a MHC class-I antigen, in any concentra tion tested (data not shown). Irrelevant murine monoclonal antibodies of the IgG2a or IgA isotype did not induce any alterations in expression of these adhesion molecules (data not shown).
Functional adhesion studies. Functional adhesion stud ies were performed to test whether the increase in expression of NKI-L16 and CD 1 lb/CD 18 after incubation with OKT3 or IXA affected the adhesion capacity of the T cells. Indeed, incubation of purified T cells with 1 ¿¿g/mL OKT3 or IXA in vitro caused a transient increase in adhesiveness of these cells to endothelial cell monolayers. Figure 4A demonstrates that after 3 minutes incubation of OKT3-coated T cells with goat antimouse Ig at 37°C, an adhesion score of 4.15 ± 0.22 was reached. Three minutes incubation of IXA-coated T cells with goat antimouse Ig at 37°C resulted in an adhesion score of 3.11 ± 0 .2 6 . The increased adhesiveness appeared to be transient, because after 30 or 60 minutes incubation, the adhesion scores decreased markedly (Fig 4A) . Dose response curves showed that maximal adhesion of T cells to endothe lium was observed with a concentration of 1 ¿¿g/mL of either OKT3 or IXA. A total of 0.1 ¿/g/mL OKT3 or IXA could still induce T-cell adhesion to endothelium, but less than that observed with 1 ¿¿g/mL of each monoclonal antibody, while with 0.01 ¿¿g/mL OKT3 or IXA, no changes in adhe sion could be detected (data not shown). As a positive con- trol, T lymphocytes were incubated with 50 ng/mL phorbol myristate acetate. This resulted in an adhesion score of 4.67 ± 0,37. As a negative control, T cells were incubated with murine IgG2a monoclonal antibodies directed against either CD4 or a MHC class-I antigen. No changes in adhesion score were observed in any of the concentrations tested (not shown). Irrelevant murine monoclonal antibodies of the IgG2a or IgA isotype did not induce any alterations in adhe sion score (Fig 4A) .
The theoretical possibility that circulating human anti mouse antibodies, which could be present in serum and can bind to the CD3 monoclonal antibody on one site and with Fc receptors on the other site, was excluded because the presence of human antimouse antibodies could not be de tected by FACS analysis after incubating CD3 monoclonal antibody-coated cells with human autologous serum (data not shown).
Blocking studies showed that coincubation of OKT3-or IXA-coated T lymphocytes with either a CD 18 or a C D !la monoclonal antibody completely inhibited the increased ad hesion as observed after 3 minutes incubation with goat antimouse Ig (Fig 4B) . Co incubation with a'CD lib mono clonal antibody resulted in partial inhibition (Fig 4B) .
DISCUSSION
In line with previous reports, the present study demon strates that administration o f the murine IgG2 a antibody i OKT3 causes an immediate peripheral T lymphocytopenia. Studies as to the causative mechanism(s) of this initial rapid disappearance of CD2+CD3+ lymphocytes are hampered by this very same phenomenon, because cells are no longer available for functional studies ex vivo. The decrease in the expression of CD62L on CD3+ T lymphocytes may reflect activation, leading to shedding of CD62L from the cell sur face.
20'21 Alternatively, it could reflect a preferential disap pearance from the peripheral blood compartment of T cells with high CD62L expression. The latter possibility is sup ported by our observation that in the experiments in vitro, no change in expression of CD62L on T cells occurred. The increase in the percentage of CDllb* and CD16+ cells within the remaining CD2+CD3~ population suggests that the observed increase in expression (MFI) of C D lla and CD1 lb and the decrease in MFI of CD62L on the remaining CD2+CD3" lymphocytes results from a selective enrichment in the peripheral blood compartment of natural killer cells, which are indeed known to have a higher CD 1 la and CD 1 lb expression,22 (unpublished results), as well as a lower CD62L expression21 as compared with T lymphocytes. The increase in MFI of C D llb on the remaining CD3 positive lymphocytes might reflect an actual upregulation of this ad hesion molecule, as was already described by Muto et al.22 These investigators showed that 30 minutes stimulation of T cells with 10 ng/mL phorbol myristate acetate at 37°C resulted in a twofold increase in the MFI of C D llb on T cells, as well as a twofold increase in the percentage of T cells expressing C D llb . This increased C D llb expression on T cells could not be blocked by cycloheximide, sug gesting the presence o f cytoplasmic (granule) stores of CDl lb in the T cells. Phorbol myristate acetate is a direct activator of protein kinase C. Activation of T cells via the T-cell receptor/CD3 complex can also stimulate the inositol phospholipid mechanism, thereby giving rise to activation of protein kinase C,12 which, in turn, may result in a rapid increase in C D llb expression.
To discriminate between the two possibilities of either redistribution o f cells between peripheral blood and other lymphoid compartments or real upregulation of adhesion molecules, the expression of these adhesion molecules was also measured on peripheral blood lymphocytes in vitro at various time points after addition of OKT3, as well as IXA, to whole blood of healthy control individuals. If IgA antibod ies can indeed cause an upregulation of adhesion molecules, this could explain the immediate peripheral blood lymphocy topenia that occurs after in vivo administration of a CD3
